Chinese IPO ASX
博源IPO媒体报道
博源IPO报价发售受到澳大利亚媒体的广泛关注。IPO的媒体报道已由《澳大利亚金融评论》和《澳大利亚人报》报道。
《澳大利亚金融评论》文章 – 博源是在澳大利亚证券交易所的第一个上市的中国房地产开发商
博源IPO开始发售
BlueMount资本高兴地宣布, 博源控股有限公司(BHL)的IPO为投资者发售了。
IPO的关键细节
- 在ASX上市的第一家中国房地产开发商。作为大型企业佳源集团的一部分,拥有丰富开发经验
- 2015年财政年度销售约A$2,000万,税后净利润约 A$610万
- 上市前估值A$5,000万,市盈率8.19x
- 在中国持有地产,并计划在澳大利亚上市后成为当地大型房地产开发商
- 公司拟在2016年财政年度派发股息
- 经验丰富的董事会和管理层
- 由德勤审计以及仲量联行进行独立估值
平仓日期 : 9月12日 2016
截止日期 : 10月12日 2016
最低投资 $2,000 澳币
博源控股有限公司首次公开发售股份(IPO)
博源控股有限公司(“本公司”)今天已向澳大利亚证券和投资委员会(ASIC)提交了IPO每股20分澳币,最低集资1500万澳币,最高2000万澳币的招股说明书。 本公司同时也向澳大利亚证券交易所(ASX)递交了上市申请。
根据每股20分和最高集资额2000万澳币,本公司估值为7000万澳币。
公司现有的业务实在浙江嘉兴王江泾的商住综合项目-佳源中心广场。 公司现已签约在新南威尔士州的Austral, Hunter Valley, 和 Marsden Park 的房地产开发项目。
- 本公司通过子公司博源投资控股(Boyuan Investment Holding Pty Ltd)已经签约获得Hunter Valley用于商业开发的两幅地产。
- 本公司通过子公司博源地产控股(Boyuan Real Estate Holding Pty Ltd)已签约获得Austral区用于住宅开发土地项目
- 本公司已签约取得了Marsden Park住宅开发项土地的看涨期权。
- 本公司具有Lindfield和Marsden Park区房地产项目的市场销售权。
公司总裁万亚丁(译音)先生指出:
“能在澳洲上市是公司向澳洲房地产开发市场扩展的重要里程碑。 我们相信澳洲的稳定政治环境,强劲的房地产市场需求和专业的劳动力将为公司和投资者们带来重大机遇。”
Boyuan Holdings Limited ASX: BHL
股权发售自2016年9月14日起至2016年9月30日结束。 预计澳大利亚证券交易所上市时间是2016年10月21日。
股权销售细节详见招股说明书。蓝山资本在澳洲和亚洲设有办公室,是股权销售的首席经办人 。
有兴趣的投资者需要填写招股说明书的申请表。投资者在投资决策之前应该全面考虑招股说明书的内容,并取得专业咨询。
股权销售开始后,招股说明书能从蓝山资本网页下载:www.bluemountcapital.com/BHL
主要发售统计
- 每股20分澳币
- 最高股份发售量是一亿股(100,000,000)
- 招股说明书发行时已被持有250,000,000股份
- 公开发售后最高可达350,000,000股份
- 根据最高认股数,公司上市市值可达$70,000,000 澳币。
- 股权发售自2016年9月14日起至2016年9月30日结束
- 预计澳大利亚证券交易所上市时间是2016年10月21日。
关于博源控股有限公司
BHL 通过在中国的分公司(博源地产控股)在嘉兴开展房地产管理和开发。 公司最近完成了位于嘉兴的佳源中心广场的商住综合项目。 目前致力于澳洲新南威尔士州的Marsden Park, Hunter Valley 和 Austral 的房地产开发机遇。
博源控股有限公司详情参见: www.boyuan.com.au
China Dairy IPO Closes Following Solid Demand
China Dairy Corporation Limited (“China Dairy or “the Company”) today announced the successful closure of its ASX IPO following solid demand from a broad range of investors raising A$17 million.
At the offer price of A$0.20 per Chess Depository Interest (“CDI”), China Dairy will have a market capitalisation of approximately A$147 million.
BlueMount Capital was the lead advisor to China Dairy Corporation.
The strong response to the IPO reflects the positive long-term fundamentals for the dairy industry, driven by Chinese consumers’ growing demand for high quality food products, including dairy products. Current milk consumption in China stands at about 20kg per capita, less than a quarter of the average world consumption level(1).
China’s relaxation of its one-child policy has also led researchers1 to estimate that the country will see an average net increase of 3 million people per year and a corresponding RMB 20 billion spent in increased demand for infant formula milk.
The robust pull factors are accompanied by a renewed push by the Chinese government to further modernise agriculture through incorporating new technologies throughout the agricultural value chain to improve productivity, as articulated in the Government’s recent 13th five-year plan.
China Dairy’s Mongolia-based Research & Development facility, which is currently being developed, will underpin the Company’s strategic focus of innovation.
Final allocation and allotment of CDI’s has now been completed. Trading is expected to commence on the 8 April 2016 under the ticker code CDC.
(1) China Agri Research, 8 Jan 2016 “Analysis and forecast on China’s dairy industry” http://en.cnagri.com/report/dairy/20160108/252923.html
About China Dairy Corporation
China Dairy Corporation (“CDC”) is a leading producer and wholesale distributor of raw milk in China; as well as breeder and seller of dairy cows.
Established in 2005, China Dairy Corporation has over 160 employees located in the Company’s operations in China.
Through a number of acquisitions, CDC has grown to become a large dairy farming operation and milk producer in China, with more than 40,000 cows owned by the Company and its partners providing it with an aggregate raw milk production capacity of over 600 tonnes per day.
CDC operates a diversified business model through which the Group expanded beyond breeding company-raised cows, to also outsourcing cattle-raising to farmer-raised and farmer-owned cows – which provides additional revenue streams through the wholesale of raw milk.
The Group has shown consistent historic growth over recent years with FY2015 revenues reaching A$79.1 million and total comprehensive income reaching A$39.5, representing a compounded annual growth rate (CAGR) of 19% and 20% respectively since FY2013. CDC’s FY2015 net profit margins of approximately 50% give it the highest profitability margins when compared to other ASX-listed dairy companies.
For more information on China Dairy Corporation, visit: www.chinadairyco.com
[1] According to a collaborative report by the OECD and the Food and Agricultural Organisation of the UN.
Invest in the First Chinese Dairy Company to List on the ASX – China Dairy Corporation Limited
BlueMount Capital is pleased to announce the Initial Public Offer for China Dairy Corporation is now available.
Key Facts & Figures
- Large producer and distributor of raw milk in China
- CDC and its partners have approx. 40,000 cows
- Very profitable approx.A$40 million NPAT FY2015
- FY2015 sales approx. A$80 million and cash at bank approx. A$70 million
- 10 year operating history
- Company intends to pay a interim and annual dividends in 2016
- Experienced board and management
- Key market: China
The Prospectus for the offer is available from BlueMount Capital and can be obtained via:
www.bluemountcapital.com/CDC
Open Date: 9 November 2015
Close Date: 5 January 2016
Minimum Investment A$ 2,000
Disclaimer
A Prospectus for the offer of Chess Depository Interests (CDI’s) in China Dairy Corporation Limited (ARBN 607 996 449) (Company) a Hong Kong registered entity was lodged with ASIC on 30 October 2015. The Prospectus may be obtained by visiting www.bluemountcapital.com/CDC. Offers of the CDI’s are only made in the Prospectus.
Investors wishing to apply for CDI’s should read the Prospectus carefully prior to deciding whether to acquire the CDI’s. Anyone wishing to acquire the CDI’s offered in the Prospectus will need to complete an application form that will be in, or accompany the Prospectus. Neither the Company, the Lead Manager or the Corporate Advisor make any representations or warranty, express or implied, or provide any guarantee regarding the likely investment returns, the performance of the CDI’s or the Company, or the suitability of the CDI’s for any investor.
Please note that any advice given by BlueMount Capital (Sydney) Pty Ltd is GENERAL advice, as the information or advice given does not take into account your particular objectives, financial situation or needs. Therefore at all times you should consider the appropriateness of the advice before you act further.
iBosses IPO On The ASX Closes
Bosses Corporation Limited ( iBosses) the parent company of iBosses Singapore has announced the successful closure of its initial public offering following solid demand from a broad range of investors.
iBosses is a training and consultancy services provider focused on entrepreneurs and early stage businesses
At the offer price of A$0.20 per share, iBosses will have a market capitalization of A$23 million
Funds raised from the IPO will be used to expand the company’s business centres and to develop the iBosses digital platform
BlueMount Capital acted as Lead Manager and Corporate Advisor to iBosses